Royalty Report: Drugs, Ophthalmological, Pharmaceuticals – Collection: 4427


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Ophthalmological
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4427

License Grant
The Japanese Licensee will help to co-develop and commercialize emixustat and emixustats backup compounds for dry AMD and other ophthalmic indications. The Agreement is referred to as the Emixustat Agreement.
License Property
If clinical trials of the products and compounds developed under the agreement are successful and other conditions are satisfied, the Licensee will co-promote those products with the Licensor in North America and will share in profits and losses. .

If the Licensor does not elect to participate in co-promotion in one or more North American countries, the Licensee will solely commercialize products developed under the agreement.

The Licensee will have sole development and commercialization rights to the products and compounds developed under the agreement in selected countries in Asia, the Pacific, the Middle East and North Africa.  

The Licensor will have sole development and commercialization rights to the products and compounds developed under the agreement in Europe and South America, and other regions, or countries outside North America and the Licensee sole territory.

Emixustat is a small molecule notable for its establishment of a new class of compounds known as visual cycle modulators. Formulated as the hydrochloride salt, emixustat hydrochloride, it is the first synthetic medicinal compound shown to affect retinal disease processes when taken by mouth.

Field of Use
The development and collaboration agreement is for the use of Emixustat for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) .

IPSCIO Record ID: 7490

License Grant
The Japanese Licensee will acquire rights to the Licensor's lead candidate, ACU-4429, and potential backup compounds in Japan and certain other Asian countries and will collaborate with the Licensor on the further development and commercialization of Collaboration Products in the Shared territory.
License Property
ACU-4429 is the Licensor's small-molecule visual cycle modulator (VCM) being developed to treat dry age-related macular degeneration (dry AMD), which occurs when light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.
Field of Use
Field means the diagnosis, treatment, palliation and/or prevention of ophthalmologic conditions, maladies and diseases, including age-related macular degeneration and diabetic retinopathy.

IPSCIO Record ID: 249885

License Grant
The Parties announced a new collaboration to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage the companys leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will pursue is the treatment of patients with Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD). A Phase 2 study in patients with GA is planned to begin in early 2019.
License Property
IONIS-FB-LRx, an antisense drug using the companys advanced LIgand Conjugated Antisense (LICA) technology, reduces the production of FB, a key protein in the complement innate immune system. FB is predominately produced in the liver and circulates throughout the vascular system, including vessels in the eye and kidney. This complement protein plays a pivotal role in an innate immunogenic cascade that, when overactivated, has been associated with the development of several complement-mediated diseases, including dry AMD.

AMD means Age-related macular degeneration.

Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.